Skin changes depend on individual factors such as baseline pigmentation, lifestyle, sun exposure, diet, and consistency of use
First violations typically result in suspensions ranging from one to four years depending on the substance and circumstances
The letters allege: Unlawful participation in the distribution and sale of compounded semaglutide or tirzepatide products Violation of FDA compounding regulations under Sections 503A and 503B Creation of public health risks through unapproved, untested products Trademark infringement and false advertising Unfair competition Recipients are typically given 10-14 days to respond in writing, certifying that they have ceased these activities
Try infusion therapy at reduced prices today and feel great all winter long
The recommendations are nonbinding, and final FDA action is still pending as of July 25, 2026
Can Dosing Errors Happen With Compounded Semaglutide